1. Abnormal hypermethylation and clinicopathological significance of FBLN1 gene in cutaneous melanoma
- Author
-
Bao-Jin Wu, Ying-Zhi Wu, Zhao-Ping Zhou, Wen-Peng Li, Rong-Qing Zhang, Wei Ding, Zhongwen Zhou, Qing-Feng Liu, and Hua Jiang
- Subjects
Adult ,Male ,Skin Neoplasms ,Tumor suppressor gene ,Biology ,medicine ,Humans ,Promoter Regions, Genetic ,Melanoma ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Calcium-Binding Proteins ,Cancer ,Promoter ,General Medicine ,Methylation ,DNA Methylation ,Middle Aged ,Prognosis ,medicine.disease ,Molecular biology ,Gene Expression Regulation, Neoplastic ,FBLN1 ,Tumor progression ,Cutaneous melanoma ,DNA methylation ,Cancer research ,Female - Abstract
Fibulin-1 (FBLN1) is involved in the progression of some types of cancer. However, the role of FBLN1 in cutaneous melanoma (CM) has not been examined. The purpose of this study was to understand the molecular mechanisms and clinical significance of FBLN1 inactivation in CM. The expression of FBLN1 mRNA in CM tissues and adjacent normal skin tissues was analyzed by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Methylation-specific polymerase chain reaction was performed to examine the methylation status of the FBLN1 gene promoter. Furthermore, the methylation status of FBLN1 was analyzed with the clinicopathological characteristics and overall survival. qRT-PCR showed FBLN1 mRNA levels in cancerous tissues to be significantly decreased compared with that in adjacent normal skin tissues. The rate of FBLN1 promoter methylation was significantly higher in CM tissues than in adjacent normal skin tissues (P
- Published
- 2013
- Full Text
- View/download PDF